180 related articles for article (PubMed ID: 37352473)
21. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
22. The Role of Precision Medicine in Child Psychiatry: What Can We Expect and When?
Posner J
J Am Acad Child Adolesc Psychiatry; 2018 Nov; 57(11):813-817. PubMed ID: 30392618
[TBL] [Abstract][Full Text] [Related]
23. Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.
Wyrofsky R; McGonigle P; Van Bockstaele EJ
Expert Opin Drug Discov; 2015 Jan; 10(1):17-36. PubMed ID: 25488672
[TBL] [Abstract][Full Text] [Related]
24. Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry.
Lozupone M; Seripa D; Stella E; La Montagna M; Solfrizzi V; Quaranta N; Veneziani F; Cester A; Sardone R; Bonfiglio C; Giannelli G; Bisceglia P; Bringiotti R; Daniele A; Greco A; Bellomo A; Logroscino G; Panza F
Expert Rev Proteomics; 2017 Sep; 14(9):809-824. PubMed ID: 28870126
[TBL] [Abstract][Full Text] [Related]
25. Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders.
Millan MJ; Goodwin GM; Meyer-Lindenberg A; Ove Ögren S
Eur Neuropsychopharmacol; 2015 May; 25(5):599-656. PubMed ID: 25836356
[TBL] [Abstract][Full Text] [Related]
26. The impact of genetics on future drug discovery in schizophrenia.
Matsumoto M; Walton NM; Yamada H; Kondo Y; Marek GJ; Tajinda K
Expert Opin Drug Discov; 2017 Jul; 12(7):673-686. PubMed ID: 28521526
[TBL] [Abstract][Full Text] [Related]
27. The Future of Digital Psychiatry.
Hariman K; Ventriglio A; Bhugra D
Curr Psychiatry Rep; 2019 Aug; 21(9):88. PubMed ID: 31410728
[TBL] [Abstract][Full Text] [Related]
28. Biomarker-Guided Tailored Therapy.
Lydiard J; Nemeroff CB
Adv Exp Med Biol; 2019; 1192():199-224. PubMed ID: 31705496
[TBL] [Abstract][Full Text] [Related]
29. Machine learning and big data: Implications for disease modeling and therapeutic discovery in psychiatry.
Tai AMY; Albuquerque A; Carmona NE; Subramanieapillai M; Cha DS; Sheko M; Lee Y; Mansur R; McIntyre RS
Artif Intell Med; 2019 Aug; 99():101704. PubMed ID: 31606109
[TBL] [Abstract][Full Text] [Related]
30. Application of Proteomic Approaches to Accelerate Drug Development for Psychiatric Disorders.
Rahmoune H; Martins-de-Souza D; Guest PC
Adv Exp Med Biol; 2017; 974():69-84. PubMed ID: 28353225
[TBL] [Abstract][Full Text] [Related]
31. A Comprehensive Review of Novel FDA-Approved Psychiatric Medications (2018-2022).
Giliberto S; Shishodia R; Nastruz M; Brar C; Bulathsinhala S; Terry J; Pemminati S; Shenoy SK
Cureus; 2024 Mar; 16(3):e56561. PubMed ID: 38646400
[TBL] [Abstract][Full Text] [Related]
32. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.
Hickie IB; Scott EM; Cross SP; Iorfino F; Davenport TA; Guastella AJ; Naismith SL; Carpenter JS; Rohleder C; Crouse JJ; Hermens DF; Koethe D; Markus Leweke F; Tickell AM; Sawrikar V; Scott J
Med J Aust; 2019 Nov; 211 Suppl 9():S3-S46. PubMed ID: 31679171
[TBL] [Abstract][Full Text] [Related]
33. Precision Psychiatry and Dual Disorders.
Szerman N; Peris L
J Dual Diagn; 2018; 14(4):237-246. PubMed ID: 30638153
[TBL] [Abstract][Full Text] [Related]
34. Precision Medicine Approaches to Mental Health Care.
Scala JJ; Ganz AB; Snyder MP
Physiology (Bethesda); 2023 Mar; 38(2):0. PubMed ID: 36099270
[TBL] [Abstract][Full Text] [Related]
35. Tetracyclines, a promise for neuropsychiatric disorders: from adjunctive therapy to the discovery of new targets for rational drug design in psychiatry.
Chaves Filho AJM; Mottin M; Soares MV; Jucá PM; Andrade CH; Macedo DS
Behav Pharmacol; 2021 Apr; 32(2&3):123-141. PubMed ID: 33595954
[TBL] [Abstract][Full Text] [Related]
36. New approaches in psychiatric drug development.
van der Doef TF; Zaragoza Domingo S; Jacobs GE; Drevets WC; Marston HM; Nathan PJ; Tome MB; Tamminga CA; van Gerven JMA; Kas MJH
Eur Neuropsychopharmacol; 2018 Sep; 28(9):983-993. PubMed ID: 30056086
[TBL] [Abstract][Full Text] [Related]
37. Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology.
Tricklebank MD; Robbins TW; Simmons C; Wong EHF
Psychopharmacology (Berl); 2021 Jun; 238(6):1417-1436. PubMed ID: 33694032
[TBL] [Abstract][Full Text] [Related]
38. Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective.
Stephenson D; Badawy R; Mathur S; Tome M; Rochester L
J Parkinsons Dis; 2021; 11(s1):S103-S109. PubMed ID: 33579873
[TBL] [Abstract][Full Text] [Related]
39. Social challenges of contemporary psychiatry.
Bouras N
Psychiatriki; 2017; 28(3):119-202. PubMed ID: 29072182
[TBL] [Abstract][Full Text] [Related]
40. CNS Drug Development: Lessons Learned Part 3: Psychiatric and Central Nervous System Drugs Developed Over the Last Decade-Implications for the Field.
Preskorn SH
J Psychiatr Pract; 2017 Sep; 23(5):352-360. PubMed ID: 28961664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
